Business Context and Reporting Period
Company: American Integrity Insurance Group, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 6, 2025 (Earliest event reported)
Reporting Period: Events occurring May 6, 2025 through May 9, 2025.
Context: The filing documents the company's Initial Public Offering (IPO) and associated corporate governance updates.
Key Financial Metrics
Capital Raised (Gross Proceeds): $100,000,000 to the Company; $10,000,000 to selling stockholders.
Offering Price: $16.00 per share.
Shares Sold: 6,875,000 total (6,250,000 by the Company; 625,000 by selling stockholders).
Net Proceeds: Not specified (gross proceeds are before underwriting discounts and estimated offering expenses).
Revenue/Profit/Cash Flow: The filing text does not provide a clear value for operating revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes
- Corporate Structure: Filed amended and restated Certificate of Incorporation and Bylaws with the State of Delaware effective May 6, 2025, in connection with the IPO.
- Public Listing: Completed IPO on May 9, 2025, listing Common Stock (Symbol: AII) on The New York Stock Exchange.
- Ownership: Transition from private to public ownership with the sale of 6,250,000 new shares by the Company.
Guidance, Outlook, and Contingencies
Over-Allotment Option: Selling stockholders granted underwriters a 30-day option to purchase up to 1,031,250 additional shares of Common Stock.
Management Commentary: The filing references a final prospectus dated May 7, 2025, for detailed descriptions of capital stock provisions but does not include specific forward-looking guidance or risk factors within this text.
Unusual Items: None reported beyond the standard IPO mechanics.
Investor Verification Checklist
- Verify the final net proceeds to the Company after deducting underwriting discounts and offering expenses.
- Review the full text of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) for specific governance provisions.
- Confirm the exercise status of the 30-day over-allotment option for 1,031,250 additional shares.
- Examine the final prospectus (File No. 333-286524) for detailed risk factors and use of proceeds not included in this 8-K summary.